Valeant Pharmaceuticals International, Inc. (VRX) Earns “Sell” Rating from Piper Jaffray Companies

Piper Jaffray Companies reaffirmed their sell rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research report sent to investors on Sunday. Piper Jaffray Companies currently has a $14.00 price target on the specialty pharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. Guggenheim started coverage on shares of Valeant Pharmaceuticals International in a research note on Saturday, June 17th. They set a buy rating and a $18.00 price target on the stock. Vetr lowered shares of Valeant Pharmaceuticals International from a strong-buy rating to a buy rating and set a $14.82 price target on the stock. in a research note on Monday, May 22nd. BidaskClub upgraded shares of Valeant Pharmaceuticals International from a hold rating to a buy rating in a research note on Thursday, June 29th. Stifel Nicolaus restated a buy rating and set a $35.00 price target on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Finally, Jefferies Group LLC restated a buy rating and set a $18.00 price target on shares of Valeant Pharmaceuticals International in a research note on Friday, July 14th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company’s stock. Valeant Pharmaceuticals International currently has an average rating of Hold and an average target price of $17.62.

Shares of Valeant Pharmaceuticals International (VRX) opened at 13.77 on Friday. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $27.84. The company has a 50-day moving average of $14.22 and a 200 day moving average of $13.18. The stock’s market cap is $4.80 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. During the same quarter in the prior year, the business posted ($0.88) EPS. Valeant Pharmaceuticals International’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Earns “Sell” Rating from Piper Jaffray Companies” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/09/20/valeant-pharmaceuticals-international-inc-vrx-earns-sell-rating-from-piper-jaffray-companies.html.

In other news, Director Schutter Richard U. De acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.87% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors increased its position in shares of Valeant Pharmaceuticals International by 3.8% during the first quarter. Nationwide Fund Advisors now owns 51,500 shares of the specialty pharmaceutical company’s stock valued at $568,000 after acquiring an additional 1,900 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of Valeant Pharmaceuticals International by 4.5% during the first quarter. Janney Montgomery Scott LLC now owns 19,573 shares of the specialty pharmaceutical company’s stock valued at $216,000 after acquiring an additional 848 shares during the last quarter. Great West Life Assurance Co. Can increased its position in shares of Valeant Pharmaceuticals International by 3.1% during the first quarter. Great West Life Assurance Co. Can now owns 248,876 shares of the specialty pharmaceutical company’s stock valued at $2,736,000 after acquiring an additional 7,511 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at about $459,000. Finally, Bank of New York Mellon Corp increased its position in shares of Valeant Pharmaceuticals International by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 407,421 shares of the specialty pharmaceutical company’s stock valued at $4,494,000 after acquiring an additional 8,944 shares during the last quarter. Hedge funds and other institutional investors own 50.47% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply